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Objective: The aims of this study were to generate normal values of aminoterminal pro–brain natriuretic peptide
in children with a bidirectional Glenn anastomosis without congestive heart failure and to test the hypothesis that
plasma levels of aminoterminal pro–brain natriuretic peptide correlate with the clinical severity of congestive
heart failure and morbidity after the Fontan operation.
Methods: Aminoterminal pro–brain natriuretic peptide plasma levels of 78 patients after the bidirectional Glenn
operation with a median age of 3.2 years and a median follow-up time of 3 years were measured by using an au-
tomated enzyme immunoassay. The severity of heart failure was quantified by using the New York University
Pediatric Heart Failure Index.
Results: The 97.5th percentile of aminoterminal pro–brain natriuretic peptide level in patients without congestive
heart failure was 339 pg/mL. Aminoterminal pro–brain natriuretic peptide levels strongly correlated with the New
York University Pediatric Heart Failure Index score (P<.001). In patients with congestive heart failure (31/78),
the aminoterminal pro–brain natriuretic peptide levels were significantly higher (median, 670 pg/mL) than in pa-
tients without congestive heart failure (median, 171 pg/mL). In 41 patients who underwent the Fontan operation,
the time to removal of chest tubes and the length of hospital stay positively correlated with the preoperative value
of aminoterminal pro–brain natriuretic peptide.
Conclusions: In children with a bidirectional Glenn anastomosis without signs of heart failure, aminoterminal
pro–brain natriuretic peptide levels were within the normal range and correlated with the severity of congestive
heart failure. Further studies are needed to determine whether aminoterminal pro–brain natriuretic peptide levels
can aide clinicians in the early detection of congestive heart failure in this patient group.
Congenital Heart Disease Lechner et alAtrial natriuretic peptide and brain natriuretic peptide (BNP)
are natriuretic hormones secreted from the atrial and ventric-
ular cardiac myocytes in response to an increase in ventric-
ular wall stretch and filling pressures.1 Hypoxia also has
been shown to be a direct stimulus for secretion of atrial
natriuretic peptide and BNP in human cardiac myocytes.2
Concentrations of BNP and its biologically inactive amino-
terminal fragment, aminoterminal pro–brain natriuretic pep-
tide (NT–pro-BNP), are of high relevance in the diagnosis
and treatment of adults with congestive heart failure
(CHF).3-6 Several investigators established age-related
reference values for BNP and NT–pro-BNP in healthy chil-
dren.7-9 Both peptides have been found to be useful markers
in a variety of cardiac diseases in children and adoles-
cents.10-15 Early and minor deteriorations of single-ventricle
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graphic analysis, and clinical signs usually appear very
late. Therefore, it can be speculated that a laboratory param-
eter like NT–pro-BNP can help to detect CHF in patients
with univentricular hearts. Thus far, data on the usefulness
of natriuretic peptides in detecting heart failure in children
with single-ventricle physiology after bidirectional Glenn
(BDG) anastomosis are limited.16-18
The aims of this prospective study were to generate
normal values of NT–pro-BNP in children with BDG but
without CHF and to test the hypothesis that preoperative
plasma levels of NT–pro-BNP correlate with the severity
of CHF, as well as with morbidity after the Fontan operation.
MATERIALS AND METHODS
From September 2004 to December 2007, NT–pro-BNP plasma levels of
78 patients after the BDG operation were measured with an automated
enzyme immunoassay (Elecsys 2010; Roche Diagnostics, Basel, Switzer-
land). The study group included 33 patients who had their routine check–
up appointment in the outpatient’s clinic and 45 hospitalized patients who
underwent either elective cardiac catheterization before the Fontan opera-
tion (41 patients) or catheter interventions (3 patients required dilatation
of aortic coarctation, and 1 patient with hypoplastic left heart syndrome
with severe insufficiency of the native aortic valve had placement of
a plug into the left ventricular [LV] outflow tract).gery c September 2009
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BDG ¼ bidirectional Glenn
BNP ¼ brain natriuretic peptide
BTS ¼ Blalock–Taussig shunt
CHF ¼ congestive heart failure
LV ¼ left ventricular
NT–pro-BNP ¼ aminoterminal pro–brain
natriuretic peptide
NYUPHFI ¼ New York University Pediatric
Heart Failure Index
RV ¼ right ventricular
For clinical assessment of CHF, all 78 patients had a chest radiogram, an
echocardiogram, and a clinical examination by an experienced pediatric car-
diologist. Because there is no special score available for assessment of heart
failure in pediatric patients with univentricular hearts, the New York Uni-
versity Pediatric Heart Failure Index (NYUPHFI),19 a general score for
quantifying the severity of heart failure in children, was used. This score
is a weighted linear combination of scores based on symptoms, physical
signs, and medical regimen (Table 1). Healthy children without heart failure
are expected to score low (2 points). In the NYUPHFI, having a single-
ventricle physiology scores withþ2 points, and therefore only a NYUPHFI
score of 5 or greater was considered to reflect heart failure in patients after
the BDG operation.
Age, sex, body weight, cardiac diagnoses, follow-up time after the BDG
operation, serum creatinine level, NT–pro-BNP level, morphology of the
systemic ventricle, NYUPHFI score, pulse oximetric saturation, and
heart/chest ratio on chest radiographic analysis were analyzed in all patients.
In the 45 patients who underwent cardiac catheterization, the following
hemodynamic parameters were additionally recorded: increase in pressure
over time (dp/dt) of the systemic ventricle, mean atrial pressure, and supe-
rior vena caval oxygen saturation. Parameters indicating postoperative
morbidity (time to removal of chest tubes, length of stay in the intensive
care unit, and total length of hospital stay) were analyzed in the 41 patients
who underwent the Fontan operation.
The study complies with the Declaration of Helsinki, and informed con-
sent was obtained from the guardian of each subject enrolled in the study.
All patient data were complete; there was no intention to replace missing
data. For the subgroup comparison of the nonnormally distributed metric
variable NT–pro-BNP (test of normality: Kolmogorov–Smirnov with Lillie-
fors significance correction) between groups, the nonparametric Mann–
Whitney U test was used. Spearman’s rank correlation coefficients were
calculated. Data are reported as medians with ranges.
RESULTS
The study group included 50 male and 28 female patients
with a median age of 3.2 years (range, 0.9–9.8 years) and
a median weight of 14.7 kg (range, 5.9–25 kg). The median
follow-up time after BDG anastomosis was 3 years (range,
0.6–5.4 years).
Anatomy and Surgical Procedures
Fifty-four patients had a systemic ventricle of right
ventricular (RV) morphology, with hypoplastic left heart
syndrome as the most common diagnosis (n ¼ 45); 20
patients had a systemic ventricle of LV morphology, with
tricuspid atresia as the most common anatomy (n ¼ 12);The Journal of Thoracic and Cand 4 patients had a systemic ventricle of undetermined
morphology.
Surgical Procedures in Patients Without CHF
Forty-seven patients had a NYUPHFI score of less than 5
and were considered not to have CHF by the pediatric
cardiologist, who was blinded to the NT–pro-BNP levels
and the results of cardiac catheterization. Twenty-seven of
47 patients without CHF had a systemic RV morphology
(20 cases of hypoplastic left heart syndrome and 7 cases of
double-outlet right ventricle with transposition of the great
arteries combined with either mitral or pulmonary atresia).
As a primary palliative step, 18 of these patients had a Nor-
wood stage I procedure with a right ventricle–pulmonary
artery conduit, 5 patients had a Norwood stage I procedure
with Blalock–Taussig shunt (BTS), 3 patients had a BTS,
and 1 patient needed no operation before the BDG anasto-
mosis. Eighteen of 47 patients had a systemic LV morphol-
ogy (10 cases of tricuspid atresia, 4 cases of tricuspid atresia
TABLE 1. New York University Pediatric Heart Failure Index
Score Signs and symptoms
þ2 Abnormal ventricular function or valve insufficiency determined
by means of echocardiographic analysis
þ2 Dependent edema or pleural effusion or ascites
þ2 Failure to thrive or cachexia
þ1 Marked cardiomegaly determined by means of radiographic
analysis or physical examination
þ1 Reported physical activity intolerance or prolonged feeding time
þ2 Poor perfusion determined by means of physical examination
þ1 Pulmonary edema determined by means of radiographic analysis
or auscultation
þ2 Resting sinus tachycardia
þ2 Retractions
Hepatomegaly
þ1 <4 cm below costal margin
þ2 >4 cm below costal margin
Observed tachypnea or dyspnea
þ1 Mild to moderate
þ2 Moderate to severe
Medications
þ1 Digoxin
Diuretics
þ1 Low-to-moderate dose
þ2 High dose or>1 diuretic
þ1 ACE inhibitors or other vasodilators or angiotensin
receptor blockers
þ1 b-Blockers
þ2 Anticoagulants not related to prosthetic valves
þ2 Antiarrhythmic agents or implantable cardiac defibrillator
Physiology
þ2 Single ventricle
Heart failure severity is determined based on signs and symptoms, medical regimen,
and ventricular physiology. Adding scores attributed to each individual criterion
derives a total score. Scores can range from 0 (no heart failure) to 30 (severe heart fail-
ure). ACE, Angiotensin-converting Enzyme.ardiovascular Surgery c Volume 138, Number 3 561
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Congenital Heart Disease Lechner et alTABLE 2. Patients’ characteristics and NT–pro-BNP levels
All patients
Systemic
LV morphology
Systemic RV
morphology
Undetermined
ventricular morphology
No. of patients 78 20 54 4
Age (y), median (range) 3.2 (0.9–9.8) 3.5 (1.7–7.8) 3 (0.9–9.8) 2.1 (1.7–3.2)
Patients with CHF (n) 31 2 27 2
NT–pro-BNP (pg/mL), median (range) 670 (290 –39,763) 366 (316–416) 721 (290–39,763) 597 (561–634)
Patients without CHF (n) 47 18 27 2
NT–pro-BNP (pg/mL), median (range) 171 (32–355) 110 (32–295) 219 (93–355) 76 (33–182)
CHF, Congestive heart failure; NT–pro-BNP, aminoterminal pro–brain natriuretic peptide.with transposition of the great arteries, 3 cases of pulmonary
atresia with intact ventricular septum, and 1 case of double-
inlet left ventricle). In this systemic LV morphology group,
the following surgical procedures were performed: 10 BTSs,
4 Norwood stage I procedures with a BTS, and 2 Norwood
stage I procedures with a right ventricle–pulmonary artery
shunt, and 2 patients needed no operation before BDG
surgery. In summary, only 6 of 18 patients without CHF
with a systemic LV morphology primarily required cardiac
surgery compared with 23 of 27 patients with a systemic
RV morphology.
Assessment of CHF and NT–Pro-BNP Levels
Thirty-one patients were considered to have clinical signs
of CHF with a NYUPHFI score of 5 or greater (median, 6.5;
range, 5–19). The following signs of CHF were found in
these 31 patients: abnormal ventricular function or relevant
valve insufficiency by means of echocardiographic analysis
(14 patients), edema (2 patients), failure to thrive (7 pa-
tients), cardiomegaly by means of radiographic analysis
(27 patients), hepatomegaly (12 patients), sinus tachycardia
(15 patients), retractions (2 patients), treatment with digoxin
(3 patients), low-dose diuretics (23 patients), high-dose
diuretics (8 patients), angiotensin-converting enzyme inhib-
itors (27 patients), and b-blocker medication (2 patients). In
patients with clinical signs of CHF (31/78 patients), the NT–
pro-BNP levels were significantly higher (median, 670 pg/
mL; range, 290–39,763 pg/mL) than in patients without
CHF (median, 171 pg/mL; range, 32–355 pg/mL; Table
2). NT–pro-BNP levels strongly correlated with the
NYUPHFI score (P< .001; Figure 1 and Table 3), but no
correlation was found between the follow-up time and
NT–pro-BNP levels (Table 3). Median oxygen saturation
measured by means of pulse oximetry of the 47 patients
without CHF was 83% (range, 71%–88%) and did not cor-
relate with NT–pro-BNP levels (Table 3).
The 95th and the 97.5th percentile of NT–pro-BNP levels
in patients without CHF were 334 pg/mL and 339 pg/mL,
respectively. NT–pro-BNP levels in patients without CHF
and a RV morphology of the systemic ventricle were signif-
icantly higher compared with those seen in patients with LV
morphology of the systemic ventricle (Table 2). Because
renal function influences NT–pro-BNP levels, we ensured562 The Journal of Thoracic and Cardiovascular Suthat patients had no signs of renal dysfunction and all serum
creatinine levels were within the normal range, with a median
of 0.31 mg/dL (range, 0.2–0.65 mg/dL).
Hemodynamic Data
Forty-five patients underwent cardiac catheterization.
There was a positive correlation found between mean atrial
pressure (median, 7 mm Hg; range, 4–15 mm Hg) and NT–
pro-BNP levels (Table 3). dp/dt measurement of the sys-
temic ventricle (median, 1005 mm Hg/s; range, 330–1445
mm Hg/s) and superior vena caval saturation (median,
67%; range, 56%–76%) negatively correlated with NT–
pro-BNP levels (Table 3).
Outcome
Six patients with severe heart failure (NYUPHFI score,
10–19) had the highest NT–pro-BNP levels (1192–39,763
pg/mL). Four of these 6 patients died from heart failure dur-
ing the study period, 1 patient underwent successful heart
transplantation, and 1 patient remained stable with medical
treatment. NT–pro-BNP levels were significantly higher (P
< .001) in the 5 patients who died of heart failure or
required heart transplantation when compared with those
seen in the other study patients who did not reach these
end points.
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FIGURE 1. Scatter plot of aminoterminal pro–brain natriuretic peptide
(NT–pro-BNP) levels (x-axis) and New York University Pediatric Heart
Failure Index scores (y-axis) in all 78 patients.rgery c September 2009
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Forty-one patients of the study group underwent the
Fontan operation. All received fenestrated Fontan tunnels,
except 2 patients with significant pulmonary arteriovenous
malformations. There were no early or late deaths in this
group. Regarding postoperative morbidity, preoperative
NT–pro-BNP levels positively correlated with time to
removal of chest tubes (median, 9 days; range, 4–42 days)
TABLE 3. Correlation of NT–pro-BNP levels with CHF and signs of
morbidity after the Fontan operation
Analyzed parameters n
Correlation
coefficient P value
Correlation of NT–pro-BNP
level and NYUPHFI score
(all patients)
78 0.899 <.001
Correlation of NT–pro-BNP
level and F/U time
(patients without CHF)
47 0.117 .44
Correlation of NT–pro-BNP
level and pulse oximetric
saturation (patients
without CHF)
47 0.026 .86
Hemodynamic data
Correlation of
NYUPHFI and dp/dt
45 0.571 <.001
Correlation of NT–pro-
BNP level and dp/dt
45 0.582 <.001
Correlation of NT–pro-BNP
level and mean atrial pressure
43 0.375 .013
Correlation of NT–pro-BNP
level and SVO2
43 0.373 .014
Morbidity after the Fontan
operation
Correlation of NT–pro-
BNP level and time
to removal of chest
tubes
41 0.406 <.01
Correlation of NT–pro-
BNP level and length
of stay in ICU
41 0.307 .051
Correlation of NT–pro-
BNP level and total
length of hospital stay
41 0.328 .036
NT–pro-BNP, Aminoterminal pro–brain natriuretic peptide; CHF, congestive heart
failure; NYUPHFI, New York University Pediatric Heart Failure Index; F/U, fol-
low-up; dp/dt, increase in pressure over time; SVO2, superior vena caval saturation;
ICU, intensive care unit.The Journal of Thoracic and Cand length of total stay in the hospital (median, 17 days;
range, 10–57 days) after the Fontan operation. The preoper-
ative NT–pro-BNP levels did not correlate with the length of
stay in the intensive care unit (median, 6 days; range, 1–34
days) after the Fontan operation.
DISCUSSION
In the present study NT–pro-BNP levels in patients later
than 6 months after BDG anastomosis without signs of
CHF were comparable with those reported in healthy chil-
dren, with the same enzyme immunoassay test kit used
(Table 4). As previously reported by Holmgren and col-
leagues,17 we found significantly higher NT–pro-BNP
levels in patients with systemic RV morphology compared
with those seen in patients with systemic LV morphology.
This finding might reflect the fact that despite apparently
normal ventricular function, the morphologic right ventricle
might be more stressed as a systemic ventricle than the
morphologic left ventricle. A further explanation for this
finding might be that patients with systemic LV morphology
experienced less neonatal cardiac surgeries and less place-
ment of a right ventricle–pulmonary artery conduit
compared with patients with systemic RV morphology.
NT–pro-BNP levels strongly correlated with the severity
of CHF assessed with the NYUPHFI, as well as with hemo-
dynamic signs of CHF invasively assessed by means of dp/
dt measurement. This was not surprising and is in accor-
dance with previous studies on the usefulness of BNP and
NT–pro-BNP levels in detecting heart failure and volume
overload in patients with congenital heart disease.10-15 Espe-
cially in patients with univentricular hearts, quantitative
assessment of ventricular function and early detection of
dysfunction is of greatest importance but is still an unsolved
problem. With regular measurements of NT–pro-BNP levels
in the individual follow-up of patients after the BDG opera-
tion, clinicians might have an additional useful tool for early
detection of CHF. However, NT–pro-BNP levels do not
allow quantitative assessment of ventricular function. In
this study the 97.5th percentile of NT–pro-BNP level in
patients without CHF was found to be 339 pg/mL (295 pg/
mL in patients with RV morphology and 345 pg/mL in
patients with LV morphology). In the routine follow-up of
patients later than 6 months after the BDG operation, higher
levels should lead to a careful work-up involving all avail-
able diagnostic modalities and to consideration of initiationTABLE 4. NT–pro-BNP levels in healthy children compared with those seen in patients after the BDG operation
Study
No. of
patients Age range (y)
NT–pro-BNP
(pg/mL), median
NT–pro-BNP
(pg/mL), range
NT–pro-BNP
upper limits (pg/mL) Remarks
Present study 47 0.9–9.8 171 32–355 334 (95th percentile) Patients after Glenn
operation without CHF
Nir and coworkers20 58 0.3–15 90 5–391 348.6 (95th percentile) Healthy children
Koch and coworkers21 46 0.4–17.5 35.5 10–298 Not available Healthy children
NT–pro-BNP, Aminoterminal pro–brain natriuretic peptide; BDG, bidirectional Glenn; CHF, congestive heart failure.ardiovascular Surgery c Volume 138, Number 3 563
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correlation found between pulse oximetric saturation and
NT–pro-BNP levels of patients without CHF, this study could
not confirm the finding of Hopkins and associates2 that hyp-
oxia stimulates secretion of BNP. The finding that superior
vena caval saturations measured during cardiac catheterization
negatively correlate with NT–pro-BNP levels is not caused
by increased NT–pro-BNP levels secondary to hypoxia; it
more likely reflects low cardiac output in patients with CHF.
The preoperatively analyzed NT–pro-BNP levels corre-
lated with the duration of excessive pleural fluid drainage after
the Fontan operation, indicating that the presence of heart fail-
ure prolongs the adaption to the special hemodynamic condi-
tions of any Fontan operation. We speculate that achieving
normal preoperative NT–pro-BNP levels by optimizing med-
ical treatment might result in less postoperative morbidity,
especially in patients with clinically undetected heart failure.
This hypothesis remains to be proved in future studies.
CONCLUSIONS
NT–pro-BNP levels of patients later than 6 months after
BDG anastomosis without CHF should not exceed those
of healthy children. Plasma NT–pro-BNP concentrations
strongly correlate with the severity of heart failure after
BDG anastomosis. Further studies are needed to determine
whether NT–pro-BNP levels can aide clinicians in the early
detection of CHF in this patient group. Patients with failure
of normalization or an increase of NT–pro-BNP levels later
than 6 months after surgical intervention should be carefully
assessed for signs of heart failure and hemodynamic prob-
lems. Preoperative optimization of ventricular function
might positively influence the postoperative morbidity of
patients undergoing the Fontan operation.
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